BUSINESS WIRE
NEW YORK--(BUSINESS WIRE)--Foresight Biotherapeutics announced today that the first patient has
been dosed in a viral conjunctivitis clinical trial. Foresight’s
proprietary lead compound, FST-100, will be tested in a
placebo-controlled, masked, and randomized multicenter clinical study
throughout the United States. The primary endpoint of the study is the
resolution of clinical signs and symptoms of acute conjunctivitis.
Secondary endpoints include a reduction in quantitative PCR (qPCR) viral
titers, eradication of infectious virus determined by cell culture
immunofluorescence assay (CC-IFA), and safety. The company anticipates
enrolling up to 100 patients.
This controlled clinical trial follows a successful pilot trial in which
the safety and efficacy of FST-100 were demonstrated. In addition, the
company recently completed and announced a successful preclinical study
in a rabbit model of adenoviral conjunctivitis.
Viral conjunctivitis or “pink eye” is the most common eye infection in
the developed world. The highly contagious infection is a frequent cause
of epidemics in the workplace, schools, medical centers and long term
care facilities. Treatment is mostly supportive as there is currently no
drug approved by the FDA for viral conjunctivitis. FST-100 is a novel
formulation of dexamethasone that includes povidone-iodine. This novel
formulation may be able to relieve the discomfort and shorten the course
of the illness. Foresight Biotherapeutics looks forward to working with
the investigators in conducting this clinical trial and advancing the
development of the program.
About Foresight Biotherapeutics, Inc.
Foresight Biotherapeutics is a drug development company focused on
diseases of the eye and ear. The company’s website is: www.foresightbiotherapeutics.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Foresight relating to matters that are not historical
facts (including without limitation those regarding the timing or
potential outcomes of research collaborations or clinical trials, any
market that might develop for any of Foresight’s product candidates are
forward-looking statements that involve risks and uncertainties,
including, but not limited to, the likelihood that future research will
prove successful, the likelihood that any product in the research
pipeline will receive regulatory approval in the United States or
abroad, the ability of Foresight and/or its partners to develop,
manufacture and commercialize, Foresight’s ability to fund such efforts
with or without partners, and other risks.